JOURNAL HOME CME HOME THIS MONTH PAST ISSUES ETOC COLLECTIONS
AUTHORS REVIEWERS EDITORIAL BOARD FEEDBACK RSS HELP
A&A International Anesthesia Research Society
QUICK SEARCH:   [advanced]


     

Anesth Analg 1990; 70:407-413
© 1990 International Anesthesia Research Society
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Aantaa, R. E.
Right arrow Articles by Scheinin, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Aantaa, R. E.
Right arrow Articles by Scheinin, H.

Dexmedetomidine Premedication for Minor Gynecologic Surgery

Riku E. Aantaa, MD, Jussi H. Kanto, MD, Mika Scheinin, MD, Antero M. I. Kallio, MD, and Harry Scheinin, MD

Departments of Anesthesiology and Pharmacology, Turku University Central Hospital, and Farmos Group Ltd., Research Center, Turku, Finland.

Abstract

The effects of four different doses (0.167, 0.33, 0.67, and 1.0 µg/kg) of dexmedetomidine, a novel {alpha}2-adrenoceptor agonist, on anesthetic requirements, hemodynamics, and plasma catecholamine levels were investigated in a single-blind fashion in 20 healthy (ASA physical status I) women scheduled for uterine dilatation and curettage. The drug was administered intravenously 15 min before anesthesia induction with thiopental. Nitrous oxide/oxygen (70%/ 30%) was used for maintenance. Dexmedetomidine was well tolerated, and no serious drug-related subjective side effects or adverse events were observed. The most prominent subjective effects were tiredness and decreased salivation. The total amount of thiopental needed to perform uterine dilatation and curettage was decreased dose-dependently from 400 ± 166 mg (mean ± SD) after 0.167 µg/kg of dexmedetomidine to 180 ± 65 mg after 1.0 µg/kg of dexmedetomidine (P = 0.028). Blood pressure, heart rate, and plasma norepinephrine levels were reduced after dexmedetomidine. The optimal dose of dexmedetomidine for single-dose intravenous premedication studies in minor surgery appears to be in the range of 0.33--0.67 µg/kg.

Key Words: PREMEDICATION, DEXMEDETOMIDINE. • SYMPATHETIC NERVOUS SYSTEM, PHARMACOLOGY—dexmedetomidine.




This article has been cited by other articles:


Home page
 Anesth. Analg.Home page
B. Tufanogullari, P. F. White, M. P. Peixoto, D. Kianpour, T. Lacour, J. Griffin, G. Skrivanek, A. Macaluso, M. Shah, and D. A. Provost
Dexmedetomidine Infusion During Laparoscopic Bariatric Surgery: The Effect on Recovery Outcome Variables
Anesth. Analg., June 1, 2008; 106(6): 1741 - 1748.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
C. S. Celly, W. N. McDonell, and W. D. Black
Cardiopulmonary Effects of the alpha 2-Adrenoceptor Agonists Medetomidine and ST-91 in Anesthetized Sheep
J. Pharmacol. Exp. Ther., May 1, 1999; 289(2): 712 - 720.
[Abstract] [Full Text]


Lippincott, Williams & Wilkins Anesthesia & Analgesia® is published for the International Anesthesia Research Society® by Lippincott Williams & Wilkins and Stanford University Libraries' HighWire Press®. Copyright 1990 by the International Anesthesia Research Society. Online ISSN: 1526-7598   Print ISSN: 0003-2999 HighWire Press
Copyright © 1990 by the International Anesthesia Research Society.